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The Medicare Prescription Drug, Improvement, and 
Modernization Act of 2003 (MMA) established a voluntary 
outpatient prescription drug benefit for Medicare beneficiaries 
that began January 1, 2006. Total expenditures for the Medicare 
drug benefit are projected to be $101.0 billion in 2016.1 Medicare 
subsidizes the cost of the program, generally paying about 
75 percent of program costs. Beneficiaries enrolling in Part D 
pay a monthly premium in addition to cost sharing and any 
deductible for their drugs. Low-income beneficiaries pay lower 
or no premiums, cost sharing, or deductibles.
The Medicare drug benefit is administered through private 
entities called prescription drug plans (PDPs) for beneficiaries in 
fee-for-service (also known as original or traditional) Medicare 
and through Medicare Advantage prescription drug (MA-PD) 
plans for beneficiaries enrolled in Medicare managed care. PDPs 
and MA-PDs perform such functions as: 
• Designing and marketing drug benefit plans 
• Negotiating drug prices with manufacturers and pharmacies
• Building and managing a network of pharmacies 
• Paying claims
• Enrolling and disenrolling beneficiaries 
• Managing a drug formulary and beneficiary appeals process
• Tracking beneficiary drug spending
Employers and unions offering retiree coverage that is at least 
as generous as Medicare’s drug benefit may qualify for retiree 
drug subsidies (RDS) to help defray the cost of providing a drug 
benefit to their Part D–eligible retirees. (See “Employers and 
Part D” section below for more on these plans.) 
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BENEFICIARY PARTICIPATION 
Medicare beneficiaries who are eligible for Medicare Part A or enrolled 
in Part B may enroll in a Medicare drug plan. In 2014, 37.9 million 
beneficiaries enrolled in a PDP or MA-PD. About 61 percent are enrolled 
in PDPs with the remainder obtaining coverage through Medicare 
Advantage drug plans. An additional 2.6 million beneficiaries enrolled 
in a drug plan through a former employer or union qualifying to receive 
RDS.2 Beneficiaries can also receive drug coverage through sources 
that do not receive Medicare subsidies including TRICARE, the Federal 
Employees Health Benefits Program for retirees, Veterans Administration 
coverage, and employer-sponsored insurance for active workers with 
Medicare as a secondary payer. It is estimated that about 10 percent of 
Medicare beneficiaries have no known source of drug coverage.
BENEFIT STRUCTURE
The Part D standard benefit for 2016 includes a $360 deductible, 25 percent 
coinsurance for covered drug spending between $360 and $3,310, and 
variable coinsurance for drug spending between $3,310 and $7,515 (a gap in 
coverage popularly known as the “donut hole”).3 After $4,850 in beneficiary 
true out-of-pocket (or “TrOOP”)4 spending is reached, catastrophic 
coverage begins and beneficiaries are only responsible for 5 percent cost 
sharing. All drug plans must offer a standard benefit plan.
The Patient Protection and Affordable Care Act (ACA), as amended 
by the Health Care and Education Reconciliation Act of 2010, enacted 
changes to the Medicare drug benefit, most notably reducing beneficiary 
cost sharing in the coverage gap. The coverage gap changes are 
implemented gradually until the gap is eliminated in 2020. In 2016, 
beneficiaries will pay 45 percent of the cost for brand name drugs and 
58 percent of the cost for generic drugs in the coverage gap. In 2020 and 
thereafter, beneficiary cost sharing in the coverage gap for brand name 
and generic drugs will be 25 percent. (FIGURE 1, next page.)
Medicare drug plans may offer nonstandard benefit plans that vary from 
this standard benefit. For example, Medicare drug plan sponsors may 
offer drug plans that are actuarially equivalent to the Medicare drug 
benefit. They may also offer plans that are more generous, or enhanced, 
as long as they also offer a basic benefit package. Nonstandard plans 
are popular with beneficiaries because they may have lower deductibles 
or cost sharing, albeit generally at higher premiums. The majority of 
beneficiaries are enrolled in nonstandard plans. 
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BENEFICIARY PREMIUMS AND PL AN PAYMENTS
Beneficiaries enrolled in PDPs typically pay a monthly premium 
for Medicare prescription drug coverage. Beneficiary premiums are 
determined by bids submitted by drug plans. A base premium of 25.5 
percent of the national average of all bids is computed. The premium 
for an individual drug plan is the sum of the base premium and the 
difference between the plan’s bid and the national average of all bids. 
Beneficiaries joining plans with bids above the national average pay 
more than the base premium, and those joining plans with bids below 
the national average pay less than the base premium with a floor of no 
premium. Medicare Advantage plans have flexibility to allocate premium 
dollars between the drug benefit and other health benefits they offer. As 
a result, many Medicare Advantage plans are able to offer drug coverage 
for $0 premium. They are also more likely than PDPs to offer coverage in 
the gap and a $0 deductible. In 2016, the average5 monthly premium for 
stand-alone PDPs is projected to be $41.46; the range of premiums is $11.40 
to $174.70. Beneficiaries with incomes higher than $85,000 ($170,000 for 
couples) will also pay a monthly surcharge ranging from $12.70 to $72.90.
FIGURE 1: Standard Drug Benefit Design, 2016
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Source: Kaiser Family Foundation, “The 
Medicare Prescription Drug Benefit,” Fact 
Sheet, October 2015, http://kff.org/medicare/ 
fact-sheet/the-medicare-prescription-drug- 
benefit-fact-sheet.
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In addition to receiving beneficiary premiums (estimated to amount 
to $14.4 billion in 20166), Medicare drug plans receive payments 
from Medicare to subsidize the cost of providing the benefit. Direct 
premium payments represent Medicare’s major subsidy to plans for all 
beneficiaries (an estimated $19.5 billion in 2016). Reinsurance subsidizes 
catastrophic expenses (an estimated $35.7 billion in 2016). Low-income 
subsidy payments subsidize premium and cost-sharing assistance for 
low-income beneficiaries (an estimated $26.4 billion in 2016).7
ASSISTANCE FOR LOW-INCOME BENEFICIARIES 
About 29 percent of Part D enrollees are expected to qualify for 
assistance in paying premiums, deductibles, and cost sharing in 2016.8 
These individuals have incomes below 150 percent of the federal poverty 
level ($17,655 for an individual and $23,895 for a couple in 2015)9 and 
few assets, and include beneficiaries dually eligible for Medicare and 
Medicaid (often referred to as “dual eligibles”). The level of extra benefits 
Medicare provides depends on the person’s income: lower income 
individuals receive more generous extra benefits including no or low 
premiums, deductibles, and cost sharing. The lowest income beneficiaries, 
dual eligibles, pay no premiums for drug plans with premiums below 
the average in an area, only very modest cost sharing for prescriptions, 
no deductible, and are not subject to the coverage gap. 
Private plans are paid extra by Medicare for low-income enrollees to 
compensate for the additional benefits they receive. Private plans will 
be paid an estimated $1,333 per enrollee for drug benefits in 2016, and an 
additional $2,141 per low-income enrollee.10
Many low-income beneficiaries, including dual eligibles, received drug 
coverage through Medicaid prior to the implementation of the Medicare 
drug benefit in 2006. In order to help finance their participation in Part 
D, the MMA requires states to contribute 90 percent of the expected 
state cost of drugs for this population, phasing down over 10 years to 
75 percent. This provision is commonly called the “clawback.” State 
payments are expected to total $9.8 billion in 2016.11
EMPLOYERS AND PART D 
Employers have several options for interacting with the Medicare drug 
benefit. Employers and union groups that provide prescription drug 
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insurance to their Medicare-eligible retired workers that is at least a 
generous as Part D coverage may apply to receive retiree drug subsidies 
(RDS) from Medicare. These payments are intended to help employers 
maintain drug coverage for their retirees, and are less expensive for 
Medicare than enrolling these beneficiaries in a Part D drug plan. In 2016 
the average RDS payment is projected to be about $659 per beneficiary.12 
Beginning in 2013, these payments were no longer tax-free for taxpaying 
employers. Employers not receiving the retiree drug subsidy may choose 
to “wrap around” Part D coverage by paying Part D premiums or 
contributing toward deductibles and/or cost sharing for their retirees. 
FORMUL ARIES AND APPEALS
The law permits Medicare drug plans to pay for most drugs approved 
by the Food and Drug Administration (FDA). However, virtually all 
PDPs use formularies, or lists of covered drugs, that effectively limit 
the number and type of drugs paid for by the plan. Plans are required 
to include a relatively broad range of drugs on their formularies to 
help prevent a plan from systematically discouraging beneficiaries 
with certain health conditions from enrolling. Plans are also prohibited 
from limiting drugs in certain protected classes, which include 
anticonvulsants, antidepressants, antineoplastics, antipsychotics, 
antiretrovirals, and immunosuppressants for the treatment of transplant 
rejection. Beneficiaries may appeal the decision of a plan to not pay (or 
require a higher copayment) for a particular drug.
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